Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Frontline: Optimal T cell activation requires the engagement of CD6 and CD166.

Hassan NJ, Barclay AN, Brown MH.

Eur J Immunol. 2004 Apr;34(4):930-40.

2.

Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions.

Bowen MA, Aruffo AA, Bajorath J.

Proteins. 2000 Aug 15;40(3):420-8. Review.

PMID:
10861932
3.

Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions.

Bowen MA, Aruffo A.

Transplant Proc. 1999 Feb-Mar;31(1-2):795-6. Review. No abstract available.

PMID:
10083342
4.

CD6-ligand interactions: a paradigm for SRCR domain function?

Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA, Bajorath J.

Immunol Today. 1997 Oct;18(10):498-504. Review.

PMID:
9357143
5.

Heat-shock proteins and the host-pathogen interaction during bacterial infection.

Stewart GR, Young DB.

Curr Opin Immunol. 2004 Aug;16(4):506-10. Review.

PMID:
15245747
6.

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.

Triebel F.

Trends Immunol. 2003 Dec;24(12):619-22. Review.

PMID:
14644131
7.

ICAM-1 co-stimulates target cells to facilitate antigen presentation.

Lebedeva T, Dustin ML, Sykulev Y.

Curr Opin Immunol. 2005 Jun;17(3):251-8. Review.

PMID:
15886114
8.

CD6 as a therapeutic target in autoimmune diseases: successes and challenges.

Pinto M, Carmo AM.

BioDrugs. 2013 Jun;27(3):191-202. doi: 10.1007/s40259-013-0027-4. Review.

PMID:
23568178
9.

ALCAM/CD166: cancer-related issues.

Weidle UH, Eggle D, Klostermann S, Swart GW.

Cancer Genomics Proteomics. 2010 Sep-Oct;7(5):231-43. Review.

PMID:
20952758
10.

Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor.

Sarukhan A, Martinez-Florensa M, Escoda-Ferran C, Carrasco E, Carreras E, Lozano F.

Curr Drug Targets. 2016;17(6):640-50. Review.

PMID:
25777272
11.

CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses.

Brown MH.

Curr Drug Targets. 2016;17(6):619-29. Review.

PMID:
26302795
12.

GITR/GITRL: more than an effector T cell co-stimulatory system.

Nocentini G, Ronchetti S, Cuzzocrea S, Riccardi C.

Eur J Immunol. 2007 May;37(5):1165-9. Review.

13.

Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses.

Santos RF, Oliveira L, Carmo AM.

Curr Drug Targets. 2016;17(6):630-9. Review.

PMID:
26028048
14.

The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations.

Kofler DM, Farkas A, von Bergwelt-Baildon M, Hafler DA.

Curr Drug Targets. 2016;17(6):651-65. Review.

PMID:
26844569
15.

CD6.

Patel DD.

J Biol Regul Homeost Agents. 2000 Jul-Sep;14(3):234-6. Review. No abstract available.

PMID:
11037061
16.

[CD5 and CD6 molecules--similarities and differences].

Rupniewska ZM, Dmoszyńska M, Roliński J.

Pol Arch Med Wewn. 1999 Mar;101(3):245-50. Review. Polish. No abstract available.

PMID:
10697403
17.

Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.

Hernández P, Moreno E, Aira LE, Rodríguez PC.

Curr Drug Targets. 2016;17(6):666-77. Review.

PMID:
26844560
18.

[Significance and the course of cell-mediated response in uveitis].

Rusiecka-Ziółkowska J.

Przegl Lek. 2002;59(2):113-4. Review. Polish.

PMID:
12152247
19.

[Frequent occurrence and biological significance of degree of polymerization in sialic acid].

Sato C.

Seikagaku. 2003 Dec;75(12):1526-30. Review. Japanese. No abstract available.

PMID:
14748146
20.

T lymphocyte surface molecules: structure and function.

Blann AD.

Med Lab Sci. 1987 Jul;44(3):220-36. Review. No abstract available.

PMID:
3323759

Supplemental Content

Support Center